• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Sarcoidosis - Pipeline Review, H2 2012 Product Image

Sarcoidosis - Pipeline Review, H2 2012

  • ID: 2335186
  • November 2012
  • 53 pages
  • Global Markets Direct

Sarcoidosis – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Sarcoidosis - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Sarcoidosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Sarcoidosis. Sarcoidosis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Sarcoidosis.
- A review of the Sarcoidosis products under development by companies and universities/research institutes based on information derived from READ MORE >

Note: Product cover images may vary from those shown

2
List of Tables 4
List of Figures 5
Introduction 6
REPORT COVERAGE 6
Sarcoidosis Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Sarcoidosis 8
Sarcoidosis Therapeutics under Development by Companies 10
Sarcoidosis Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Pre-Clinical Stage Products 15
Comparative Analysis 15
Sarcoidosis Therapeutics – Products under Development by Companies 16
Sarcoidosis Therapeutics – Products under Investigation by Universities/Institutes 17
Companies Involved in Sarcoidosis Therapeutics Development 18
Johnson & Johnson 18
Celgene Corporation 19
Mondobiotech Holding AG 20
Centocor Ortho Biotech, Inc. 21
Sarcoidosis – Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
PDA-001 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
ustekinumab - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
rituximab - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
adalimumab - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
atorvastatin calcium - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
pentoxifylline - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
golimumab - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Influenza Vaccine - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
thalidomide - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
DasKloster-011201 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
DasKloster-018201 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
aviptadil - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
thymopentin - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Sarcoidosis Therapeutics – Drug Profile Updates 44
Sarcoidosis Therapeutics – Discontinued Products 49
Sarcoidosis Therapeutics - Dormant Products 50
Sarcoidosis – Product Development Milestones 51
Featured News & Press Releases 51
Mar 09, 2011: MondoBIOTECH’s Sarcoidosis Drug Thymopentin Receives Orphan Drug Designation From FDA 51
Appendix 52
Methodology 52
Coverage 52
Secondary Research 52
Primary Research 52
Expert Panel Validation 52
Contact Us 53
Disclaimer 53

List of Tables
Number of Products Under Development for Sarcoidosis, H2 2012 8
Products under Development for Sarcoidosis – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 10
Number of Products under Investigation by Universities/Institutes, H2 2012 11
Comparative Analysis by Late Stage Development, H2 2012 12
Comparative Analysis by Mid Clinical Stage Development, H2 2012 13
Comparative Analysis by Early Clinical Stage Development, H2 2012 14
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 15
Products under Development by Companies, H2 2012 16
Products under Investigation by Universities/Institutes, H2 2012 17
Johnson & Johnson, H2 2012 18
Celgene Corporation, H2 2012 19
Mondobiotech Holding AG, H2 2012 20
Centocor Ortho Biotech, Inc., H2 2012 21
Assessment by Monotherapy Products, H2 2012 22
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Stage and Molecule Type, H2 2012 26
Sarcoidosis Therapeutics – Drug Profile Updates 44
Sarcoidosis Therapeutics – Discontinued Products 49
Sarcoidosis Therapeutics – Dormant Products 50

List of Figures
Number of Products under Development for Sarcoidosis, H2 2012 8
Products under Development for Sarcoidosis – Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 11
Late Stage Products, H2 2012 12
Mid Clinical Stage Products, H2 2012 13
Early Clinical Stage Products, H2 2012 14
Pre-Clinical Stage Products, H2 2012 15
Assessment by Monotherapy Products, H2 2012 22
Assessment by Route of Administration, H2 2012 23
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Molecule Type, H2 2012 25
Assessment by Stage and Molecule Type, H2 2012 26

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos